Bjurenfalk Zusanna, Cosmo Alva, Simonsson Otto, Ran Caroline
Department of Neuroscience, Centre for Cluster Headache, Karolinska Institutet, Stockholm, Sweden.
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
J Psychopharmacol. 2025 Sep;39(9):968-975. doi: 10.1177/02698811251324372. Epub 2025 Mar 12.
Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin are potentially promising new treatment candidates for these conditions.
The aim of the present study was to investigate the possible relationship between the lifetime use of classic psychedelics and frequent bad headaches in a large British cohort sample.
Using data ( = 11,419) collected in 1999-2000 as part of the 1958 British National Child Development Study, this cross-sectional study used multiple logistic regression, controlling for a range of potential confounders, to test the hypothesis that lifetime use of classic psychedelics would be associated with lower odds of having frequent bad headaches.
Lifetime use of classic psychedelics was associated with 25% lower odds of having frequent bad headaches (adjusted odds ratio = 0.75, 95% CI: 0.59-0.95, = 0.016).
The results of the present study add to the literature suggesting classic psychedelics as a possible future prophylactic treatment option for primary headache disorders.
偏头痛和丛集性头痛是两种传统治疗方法有限的原发性头痛疾病。经典致幻物质，如麦角酸二乙酰胺（LSD）和裸盖菇素，可能是治疗这些疾病的有前景的新候选药物。
本研究的目的是在一个大型英国队列样本中调查经典致幻剂的终生使用与频繁严重头痛之间的可能关系。
本横断面研究使用了1999 - 2000年收集的数据（n = 11419），作为1958年英国全国儿童发展研究的一部分，采用多元逻辑回归，控制一系列潜在混杂因素，以检验经典致幻剂的终生使用与频繁严重头痛几率较低相关的假设。
经典致幻剂的终生使用与频繁严重头痛的几率降低25%相关（调整后的优势比 = 0.75，95%置信区间：0.59 - 0.95，P = 0.016）。
本研究结果补充了文献，表明经典致幻剂可能是未来原发性头痛疾病的预防性治疗选择。
